STING1 and neoplasm: Given that ROC1 cold tumors lack the infiltration of antigen-specific effector T cells, we next assessed whether a STING agonist could convert a cold tumor to a warm tumor and thereby improve the efficacy of an anti-PD-1 ICI50,51.